Therapy Areas: Oncology
Racura Oncology doses first patient in Phase 1 lung cancer trial
26 June 2026 - Australian-based clinical-stage biopharmaceutical company Racura Oncology Limited (ASX:RAC) announced on Thursday that the first patient has been dosed with RC220 in HARNESS-1, a Phase ...
LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation
26 June 2026 - LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Brea...
FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer
25 June 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has approved Keytru...
Biosidus partners with Mubadala Bio in the UAE
25 June 2026 - Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Inve...
Natera Signatera gains PMDA approval in Japan for colorectal cancer testing
24 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Wednesday that its Signatera test has received regulatory approval from Japan's Pharmaceuticals a...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...